Coya Therapeutics, Inc. (COYA) News
Follow Coya Therapeutics, Inc. (COYA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Coya Plans ALS Trial Extension, Pushes FTD Trial to 2027
Coya expects to begin an open-label extension of its Phase 2/3 ALSTARS trial of COYA 302 in ALS in November 2026. The company now expects its Phase 2 FTD trial to start in 2027; cash runway guidance remains into H2 2027.
EQUITY | Oct 14, 2026, 12:01 PM UTC
L
Coya Therapeutics Price Target Maintained With a $16.00/Share by BTIG
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 04:22 PM UTC
L
Coya Therapeutics enrolls 100th patient in Phase 2/3 ALSTARS trial, full enrollment on track for early Q2 2027
Coya Therapeutics announced enrollment of its 100th patient in the Phase 2/3 ALSTARS trial of COYA 302 and expects full enrollment to allow topline data in early Q2 2027.Key Highlights:Original SEC Filing: Coya Therapeut
REGULATION | Sep 15, 2026, 12:23 PM UTC
L
Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today
NEWS | Sep 15, 2026, 12:06 PM UTC
L
Coya Therapeutics publishes preclinical study on COYA 303 combination effects
Coya Therapeutics said it has published preclinical results for COYA 303 in the International Journal of Molecular Sciences, describing combination immunomodulatory effects in a model of peripheral and CNS inflammation.
EQUITY | Sep 08, 2026, 12:05 PM UTC
L
COYA Treg-directed combo therapies show early promise in ALS, FTD
TradingView News reports COYA’s Treg-directed combination therapies show promising early clinical signals in ALS and FTD, with key data expected in 2027.
EQUITY | Sep 01, 2026, 03:07 PM UTC